While evidence for HDAC inhibitors as treatments is only now emerging for some of these age‐related diseases (such as liver dysfunction or sarcopenia), others have large amounts of evidence and clinical trials are underway (such as for neurodegeneration). This evidence concerns the gene HDAC9 and Decreased liver function.